Statin effects beyond lipid lowering--are they clinically relevant?
Bonetti
P O
PO
Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
Lerman
L O
LO
Napoli
C
C
Lerman
A
A
D000975:Antioxidants / Q000378:metabolism; D017209:Apoptosis / Q000502:physiology; D001682:Biological Availability; D001792:Blood Platelets / Q000502:physiology; D006332:Cardiomegaly / Q000188:drug therapy; D016228:Endothelial Growth Factors / Q000502:physiology; D019332:Endothelin-1 / Q000096:biosynthesis; D004730:Endothelium, Vascular; D005342:Fibrinolysis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000097:blood / Q000517:prevention & control*; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology; D007962:Leukocytes / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008222:Lymphokines / Q000502:physiology; D008262:Macrophage Activation; D023421:Models, Animal; D008954:Models, Biological; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D009569:Nitric Oxide / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000975:Antioxidants; D016228:Endothelial Growth Factors; D019332:Endothelin-1; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D036341:Intercellular Signaling Peptides and Proteins; D008055:Lipids; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D009569:Nitric Oxide